Biogen Idec Suggests PML Risk Manageable For Tecfidera, After Reporting First Case
This article was originally published in The Pink Sheet Daily
Executive Summary
Deadly brain disease casts shadow over a quarter in which the company reports progress on new launches, including hemophilia, but PML occurred in only one in 100,000 treated and experience suggests risk can be managed.